Phosphagenics Limited (“Phosphagenics”) (ASX: POH) announced today the successful completion of large-scale chronic toxicology studies on its patented transdermal morphine formulation, TPM-01/Morphine, and the carrier platform gel technology, TPM-01. The results of this pre-clinical study will form part of a US Food and Drug Administration Investigational New Drug data package for the indication of chronic pain.
